Lv41
442 积分 2022-05-13 加入
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
8小时前
待确认
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
4天前
已完结
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
5天前
已完结
The cancer-immunity cycle: Indication, genotype, and immunotype
9天前
已完结
Advances in current and emerging immunotherapies for ovarian cancer
11天前
已完结
Homologous recombination deficiency in Ovarian cancer: The game-changer for first-line maintenance therapy
13天前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
13天前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
15天前
已完结
Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation
17天前
已完结
Whole–genome characterization of chemoresistant ovarian cancer
17天前
已完结
皖公网安备34019202002308
